IAPP and diabetes mellitus: Thought pramlintide brought remarkable benefits for management of diabetes [50,51], diabetic individuals still face limitations: i) amylin must be injected separately from insulin [52] since its has been observed that amylin interacts with insulin [22,53,54]; ii) restoration of the basal amylin level is not achieved with the products currently available; iii) there is no therapeutics based on homologous human amylin.